WO2001035932A3 - Sustained drug delivery from structural matrices - Google Patents
Sustained drug delivery from structural matrices Download PDFInfo
- Publication number
- WO2001035932A3 WO2001035932A3 PCT/US2000/031754 US0031754W WO0135932A3 WO 2001035932 A3 WO2001035932 A3 WO 2001035932A3 US 0031754 W US0031754 W US 0031754W WO 0135932 A3 WO0135932 A3 WO 0135932A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drugs
- control over
- drug delivery
- matrices
- vivo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU16228/01A AU1622801A (en) | 1999-11-18 | 2000-11-17 | Sustained drug delivery from structural matrices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16619199P | 1999-11-18 | 1999-11-18 | |
US60/166,191 | 1999-11-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001035932A2 WO2001035932A2 (en) | 2001-05-25 |
WO2001035932A3 true WO2001035932A3 (en) | 2002-03-07 |
Family
ID=22602185
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/031754 WO2001035932A2 (en) | 1999-11-18 | 2000-11-17 | Sustained drug delivery from structural matrices |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU1622801A (en) |
WO (1) | WO2001035932A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002542183A (en) | 1999-04-16 | 2002-12-10 | ノボ ノルディスク アクティーゼルスカブ | Moldable dry pharmaceutical formulation |
AUPR289601A0 (en) * | 2001-02-05 | 2001-03-01 | Commonwealth Scientific And Industrial Research Organisation | Method of tissue repair |
AU2002227792B2 (en) * | 2001-02-05 | 2007-12-13 | Industrial Technology Research Institute | Methods and devices for tissue repair |
GB0115320D0 (en) | 2001-06-22 | 2001-08-15 | Univ Nottingham | Matrix |
WO2004108810A1 (en) * | 2003-06-06 | 2004-12-16 | Humanautocell Gmbh | Matrix, cell implantation and method for their production and use |
US7473678B2 (en) | 2004-10-14 | 2009-01-06 | Biomimetic Therapeutics, Inc. | Platelet-derived growth factor compositions and methods of use thereof |
AU2005323062A1 (en) * | 2005-01-04 | 2006-07-13 | The Brigham And Women's Hospital, Inc. | Sustained delivery of PDGF using self-assembling peptide nanofibers |
SI2347775T1 (en) | 2005-12-13 | 2020-10-30 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
EP1991282B1 (en) | 2006-02-09 | 2013-06-19 | BioMimetic Therapeutics, LLC | Compositions and methods for treating bone |
JP5484047B2 (en) | 2006-06-30 | 2014-05-07 | バイオミメティック セラピューティクス, エルエルシー | PDGF-biomatrix composition and method for treating rotator cuff injury |
US9770535B2 (en) | 2007-06-21 | 2017-09-26 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
ES2358703B1 (en) * | 2007-11-14 | 2012-03-21 | Universidad Del Pais Vasco | EMPLOYMENT OF MICROPART�? CULAS FOR USE AS VACCINES AND THE RELEASE OF BIOLOGICALLY ACTIVE MOLECULES. |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
AU2009215188B2 (en) | 2008-02-13 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Continuous cell programming devices |
WO2009146456A1 (en) * | 2008-05-30 | 2009-12-03 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
EP2461828B1 (en) | 2009-07-31 | 2017-06-21 | President and Fellows of Harvard College | Programming of cells for tolerogenic therapies |
US8492339B2 (en) * | 2009-10-26 | 2013-07-23 | Empire Technology Development Llc | Angiogenesis promoted by caged growth factors |
NZ601559A (en) | 2010-02-22 | 2014-10-31 | Biomimetic Therapeutics Llc | Platelet-derived growth factor compositions and methods for the treatment of tendinopathies |
EP2542230A4 (en) | 2010-03-05 | 2013-08-28 | Harvard College | Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1 |
US9693954B2 (en) * | 2010-06-25 | 2017-07-04 | President And Fellows Of Harvard College | Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
PT2624873T (en) | 2010-10-06 | 2020-03-04 | Harvard College | Injectable, pore-forming hydrogels for materials-based cell therapies |
WO2012064697A2 (en) | 2010-11-08 | 2012-05-18 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
EP2701753B1 (en) | 2011-04-27 | 2018-12-26 | President and Fellows of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
EP3417876B1 (en) | 2011-04-28 | 2021-03-31 | President and Fellows of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
JP6062426B2 (en) | 2011-06-03 | 2017-01-18 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | In situ antigen-producing cancer vaccine |
US8753309B2 (en) | 2011-06-24 | 2014-06-17 | The Invention Science Fund I, Llc | Device, system, and method including micro-patterned cell treatment array |
WO2013158673A1 (en) | 2012-04-16 | 2013-10-24 | President And Fellows Of Harvard College | Mesoporous silica compositions for modulating immune responses |
EP3137105A4 (en) | 2014-04-30 | 2017-12-27 | President and Fellows of Harvard College | Combination vaccine devices and methods of killing cancer cells |
WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
JP7094533B2 (en) | 2015-04-10 | 2022-07-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Immune cell capture device and its manufacture and use |
US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
US11555177B2 (en) | 2016-07-13 | 2023-01-17 | President And Fellows Of Harvard College | Antigen-presenting cell-mimetic scaffolds and methods for making and using the same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998044027A1 (en) * | 1997-03-31 | 1998-10-08 | The Regents Of The University Of Michigan | Open pore biodegradable matrices |
WO1999058656A2 (en) * | 1998-05-13 | 1999-11-18 | The Regents Of The University Of Michigan | Sustained dna delivery from structural matrices |
WO2000056375A2 (en) * | 1999-03-19 | 2000-09-28 | The Regents Of The University Of Michigan | Mineralization and cellular patterning on biomaterial surfaces |
-
2000
- 2000-11-17 WO PCT/US2000/031754 patent/WO2001035932A2/en active Search and Examination
- 2000-11-17 AU AU16228/01A patent/AU1622801A/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998044027A1 (en) * | 1997-03-31 | 1998-10-08 | The Regents Of The University Of Michigan | Open pore biodegradable matrices |
WO1999058656A2 (en) * | 1998-05-13 | 1999-11-18 | The Regents Of The University Of Michigan | Sustained dna delivery from structural matrices |
WO2000056375A2 (en) * | 1999-03-19 | 2000-09-28 | The Regents Of The University Of Michigan | Mineralization and cellular patterning on biomaterial surfaces |
Non-Patent Citations (2)
Title |
---|
GOPFERICH A: "Bioerodible implants with programmable drug release", JOURNAL OF CONTROLLED RELEASE,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 44, no. 2, 17 February 1997 (1997-02-17), pages 271 - 281, XP004015255, ISSN: 0168-3659 * |
SHEA L D: "DNA delivery from polymer matrices for tissue engineering", NATURE BIOTECHNOLOGY,US,NATURE PUBLISHING, vol. 17, no. 6, June 1999 (1999-06-01), pages 551 - 554, XP002121278, ISSN: 1087-0156 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9161967B2 (en) | 2006-06-30 | 2015-10-20 | Biomimetic Therapeutics, Llc | Compositions and methods for treating the vertebral column |
US8870954B2 (en) | 2008-09-09 | 2014-10-28 | Biomimetic Therapeutics, Llc | Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries |
Also Published As
Publication number | Publication date |
---|---|
AU1622801A (en) | 2001-05-30 |
WO2001035932A2 (en) | 2001-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2001035932A3 (en) | Sustained drug delivery from structural matrices | |
WO2001089479A3 (en) | Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds | |
CA2193337A1 (en) | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients | |
CA2338358A1 (en) | Compounds and compositions for delivering active agents | |
CA2329005A1 (en) | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems | |
EP0993831A3 (en) | Compounds and compositions for delivering active agents | |
CA2233108A1 (en) | Complex of y-cyclodextrin and retinol or retinol derivatives, processes for their preparation and their use | |
CA2067228A1 (en) | Drug delivery system, method for preparing the same and use thereof | |
AU6675198A (en) | Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use | |
HK1048986A1 (en) | 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds. | |
EP2213302A3 (en) | DR4 antibodies and uses thereof | |
AU4155897A (en) | Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles | |
AU1307399A (en) | Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same | |
CA2287534A1 (en) | Biodegradable microparticles for the sustained delivery of therapeutic drugs | |
AU2542500A (en) | Lipoprotein complexes and compositions containing them | |
WO2001034641A3 (en) | Antimicrobial activity of the first cationic cluster of human lactoferrin | |
WO2000076528A3 (en) | Pharmaceutical preparation containing proteins | |
HUP0003207A2 (en) | Proliposome powders for inhalation stabilised by tocopherol, pharmaceutical compositions containing the same and the use of them | |
AU2001289653A1 (en) | Composite solid shaped articles for the controlled delivery of biologically active ingredients | |
AU2003296602A1 (en) | Quaternary compounds comprising propolis as the active substance | |
AU1594897A (en) | Solid instant-release forms of administration and process for producing the same | |
AU1258000A (en) | Novel agarofuan derivatives, their preparation, pharmaceutical composition containing them and their use as medicine | |
CA2356306A1 (en) | Sulfated phosphatidylinositols, their preparation and use | |
AU7305496A (en) | Novel acid pyrazole derivatives, preparation method therefor, use thereof as drugs, novel use therefor, and pharmaceutical compositions containing such derivatives | |
WO2004004705A3 (en) | Pharmaceutical formulations for preparing drink products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |